Neuroprotective Effects of Caspase-3 Inhibition on Functional Recovery and Tissue Sparing After Acute Spinal Cord Injury
Authors:
- Paul M. ArnoldPAPaul M. Arnold
- Neal G. HaynesNHNeal G. Haynes
- Syed AmeenuddinSASyed Ameenuddin
- Mohammed FarooqueMFMohammed Farooque
- Karen SantaCruzKSKaren SantaCruz
- Barry W. FestoffBFBarry W. Festoff
- 1 October 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Spine
- Vol. 33 (21) , 2269-2277
Abstract
We used gene microarrays and found that caspase-related death genes were upregulated. We tested caspase inhibition and evaluated its effect on the spinal cord after traumatic injury. The logical extension of previous studies was to determine whether downstream CASP genes might also be involved and whether inhibition might prevent injury-induced cell death. Apoptotic cell death occurs in all endogenous cellular compartments of the spinal cord, peaking at 3 days after injury in neurons, astrocytes, and microglia. The downstream effector caspase-3 cleaves several important cellular sites after being activated by upstream initiator caspases. Along with others, we have previously identified caspase signature cleavage of PARP, alpha-fodrin, and DFF45/ICAD in the injured rat spinal cord. We also showed rapid upregulation of caspase-3 gene expression along with localization of active caspase-3 in neurons and activated microglia after SCI. Others have reported that a more general active-site mimetic peptide ketone, benzylocarbonyl-Val-Ala-Asp-fluromethylketone (zVAD-fmk) was neuroprotective after rat spinal cord injury (SCI). In this study, we administered the caspase-3 subfamily tetrapeptide cell permeable inhibitor Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me) fluoromethyl ketone (DEVD-fmk) intraperitoneally 1 hour after laminectomy and moderate (25 g cm force) SCI in rats. RESULTS.: We used the open field locomotor rating (LRS) over a 14-day course and found statistically significant improvement in DEVD-fmk-treated rats, LRS, 9.8 +/- 0.93 SEM, compared with vehicle, 6.6 +/- 0.4 (P < 0.05). Histologic analysis of percent spinal cord tissue volume spared was 50% greater for DEVD-fmk versus control (P < 0.5). These results indicate neuroprotection at both the cellular level and with substantial functional recovery, suggesting caspase-3 inhibition may be a viable therapy in the early hours after experimental SCI.Keywords
This publication has 74 references indexed in Scilit:
- Central nervous system hydatidosis in Turkey: a cooperative study and literature survey analysis of 458 casesJournal of Neurosurgery, 2000
- A Critical Appraisal of the Reporting of the National Acute Spinal Cord Injury Studies (II and III) of Methylprednisolone in Acute Spinal Cord InjuryJournal of Spinal Disorders, 2000
- High dose methylprednisolone in the management of acute spinal cord injury – a systematic review from a clinical perspectiveSpinal Cord, 2000
- Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow upJournal of Neurosurgery, 1998
- Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord InjuryJAMA, 1997
- ▪ Spinal Cord Injury: Role of Steroid TherapySpine, 1994
- The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in ratsJournal of Neurosurgery, 1994
- Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up dataJournal of Neurosurgery, 1992
- A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord InjuryNew England Journal of Medicine, 1990
- Edema Development and Ion Changes in Rat Spinal Cord After Impact Trauma: Injury Dose–Response StudiesJournal of Neurotrauma, 1990